Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
Annals of Internal Medicine
|
May 1, 1970
Prolonged immunological disorder terminating in hematological malignancy: A human analogue of animal disease?
R R Joseph, C D Tourtellotte, W E Barry, et al.
Cancer Research
|
March 1, 1977
cis-dichlorodiammineplatinum(II) chemotherapy in experimental murine myeloma MOPC 104E
V K Ghanta, M T Jones, D A Woodard, et al.
Cancer
|
November 1, 1978
BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease
J R Durant, R A Gams, E Velez-Garcia, et al.
Journal of the Medical Association of the State of Alabama
|
June 1, 1970
A proposal for the management of Hodgkin's disease at The University of Alabama Medical Center Birmingham, Alabama
D J Brascho, J R Durant, F G Moody, et al.
Biochemical and Biophysical Research Communications
|
December 31, 1982
Human tumors as examined by in vivo 31P NMR in athymic mice
W T Evanochko, T C Ng, J D Glickson, et al.
Annals of Internal Medicine
|
February 1, 1979
Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU)
J R Durant, M J Norgard, T M Murad, et al.
Methods of Information in Medicine
|
July 1, 1976
Clinical algorithms for cancer chemotherapy--systems for community-based consultant-extenders and oncology centers
E Mesel, D D Wirtschafter, J T Carpenter, et al.
Cancer
|
October 11, 1975
A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) vs. nitrogen mustard in advanced Hodgkin's disease
C M Huguley, J R Durant, R R Moores, et al.
Blood
|
October 1, 1979
Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma
H J Cohen, H R Silberman, W E Larsen, et al.
Cancer
|
March 15, 1982
A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy
C M Balch, R V Smalley, A A Bartolucci, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
Annals of Internal Medicine
|
May 1, 1970
Prolonged immunological disorder terminating in hematological malignancy: A human analogue of animal disease?
R R Joseph, C D Tourtellotte, W E Barry, et al.
Cancer Research
|
March 1, 1977
cis-dichlorodiammineplatinum(II) chemotherapy in experimental murine myeloma MOPC 104E
V K Ghanta, M T Jones, D A Woodard, et al.
Cancer
|
November 1, 1978
BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease
J R Durant, R A Gams, E Velez-Garcia, et al.
Journal of the Medical Association of the State of Alabama
|
June 1, 1970
A proposal for the management of Hodgkin's disease at The University of Alabama Medical Center Birmingham, Alabama
D J Brascho, J R Durant, F G Moody, et al.
Biochemical and Biophysical Research Communications
|
December 31, 1982
Human tumors as examined by in vivo 31P NMR in athymic mice
W T Evanochko, T C Ng, J D Glickson, et al.
Annals of Internal Medicine
|
February 1, 1979
Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU)
J R Durant, M J Norgard, T M Murad, et al.
Methods of Information in Medicine
|
July 1, 1976
Clinical algorithms for cancer chemotherapy--systems for community-based consultant-extenders and oncology centers
E Mesel, D D Wirtschafter, J T Carpenter, et al.
Cancer
|
October 11, 1975
A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) vs. nitrogen mustard in advanced Hodgkin's disease
C M Huguley, J R Durant, R R Moores, et al.
Blood
|
October 1, 1979
Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma
H J Cohen, H R Silberman, W E Larsen, et al.
Cancer
|
March 15, 1982
A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy
C M Balch, R V Smalley, A A Bartolucci, et al.
Page
of 8